Anti-xCT Antibody, clone 3A12

Quality Control Testing

Evaluated by Western Blotting in HepG2 cell lysate.

Western Blotting Analysis: A 1:125 dilution of this antibody detected Cystine/glutamate transporter (xCT) in HepG2 cell lysates.

Tested Applications

Western Blotting Analysis: A 1:125 dilution from a representative lot detected Cystine/glutamate transporter (xCT) in A549 cell lysate.

Immunocytochemistry Analysis: A 1:50 dilution from a representative lot detected V (xCT) in A549 cells.

Western Blotting Analysis: A representative lot detected Cystine/glutamate transporter (xCT) in Western Blotting applications (Doll, S., et al. (2019). Nature.;575(7784):693-698).

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

Anti-xCT, clone 3A12, Cat. No. MABC1637, is a rat monoclonal antibody that detects Cystine/glutamate transporter (xCT) and is tested for use in Immunocytochemistry and Western Blotting.

Clone 3A12 is a rat monoclonal antibody that detects human Cystine/glutamate transporter (SLC7A11). It targets an epitope within 21 amino acids from the N-terminal, first cytoplasmic domain.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Cystine/glutamate transporter (UniProt: Q9UPY5; also known as Amino acid transport system xc-, Calcium channel blocker resistance protein CCBR1, Solute carrier family 7 member 11, xCT) is encoded by the SLC7A11 gene (Gene ID: 23657) in human. xCT is a multi-pass membrane protein with seven cytoplasmic domains, twelve transmembrane domains, and six extracellular domains. It serves as a sodium-independent, high-affinity exchange of anionic amino acids and has high specificity for anionic form of cystine and glutamate. Its expression is induced in response to reactive oxygen species (ROS)-inducing agents such as hydrogen peroxide, leading to enhanced glutathione (GSH) production. Higher expression of xCT is reported in astrocytes where it acts as an antiporter that couples the uptake of one molecule of cystine with the export of one molecule of glutamate. It is overexpressed in several cancers, including non-small cell lung cancer, breast cancer, and liver cancer and its elevated levels are associated with poor outcome. It has also been implicated in promoting tumorigenesis through its antioxidant function that supports cancer cell proliferation, matrix invasion, and tumor growth. Normally, KRAS is shown to protect fibroblasts against oxidative damage by stimulating xCT to enhance glutathione levels. However, in cancer cells xCT expression and activity can be induced by mutant KRAS, which can favor tumor growth. (Ref.: Lim, JKM., et al. (2019). Proc. Natl. Acad. Sci. USA. 116(19); 9433-9442).

Ovalbumin-conjugated linear peptide corresponding to 21 amino acids from the N-terminal, first cytoplasmic domain of human Cystine/glutamate transporter (SLC7A11).

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Purified rat monoclonal antibody IgG2a in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Recommend storage at +2°C to +8°C. For long term storage antibodies can be kept at -20°C. Avoid repeated freeze-thaws.